Artificial Intelligence

A new report on AI in the energy sector reveals a critical truth for medicine: general-purpose AI is not ready for high-stakes decisions without human experts.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

A partnership between ZEDEDA and Sonny's Enterprises reveals how edge orchestration is transforming traditional industry and creating a blueprint for the future.

Aviz Networks just launched a certified SONiC distribution, aiming to break down the barriers of complexity and support that have kept open networking on the sidelines.

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

Veritone is letting police control their own AI, offering a new model for data security that could transform law enforcement and rebuild public trust.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.

OutSystems' #1 G2 ranking isn't just an award; it signals a seismic shift where AI-powered low-code and user satisfaction are the new currencies.

Vancouver's SimplyAsk.ai and Mexican telecom giant Axtel partner to tackle AI's high failure rate, aiming to unlock a multi-billion dollar market.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

A new initiative empowers local leaders to deploy a data-backed 'catch-up' learning method, aiming to solve Africa's foundational education crisis.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.